Alaunos Therapeutics, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 09 Oct 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 15 Apr 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Pledge-related SEC filings found
Found 1 SEC Form 4 filing(s) mentioning 'pledged' for this company's insiders. No exact percentage is available from this source (unlike India's BSE disclosures) — this flags that pledge-related activity exists and is worth reviewing directly on SEC EDGAR, not a computed magnitude.
More details →Alaunos Therapeutics, Inc. — Overview & Financial Snapshot
Alaunos Therapeutics, Inc. (NasdaqCM: TCRT) is a Healthcare company, ranked #6,006 of 6,774 companies globally and #3,386 of 4,000 in United States on PositoAI, with a Positivity Score of 12,393. Its market capitalisation is ₹83.99 Cr ($8.90M), P/E ratio is -1.7 and P/B ratio is 13.65. It currently has 2 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 1/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →